Protein kinase a type I: A target for cancer therapy

Clinical Cancer Research

Volumn 8, Issue 2, 2002, Pages 303-304

  Tortora, Giampaolo ^a   Ciardiello, Fortunato ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

APOPTOSIS; CANCER THERAPY; CARCINOGENESIS; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; ENZYME ACTIVITY; HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 0036187489     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (11)

1. cAMP-dependent protein kinase: Role in normal and malignant growth
2. Targeting of epidermal growth factor receptor and protein kinase A: Molecular basis and therapeutic applications
3. Antisense DNA-targeting protein kinase A-RIα subunit. A novel approach to cancer treatment
4. Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production
5. Antisense DNAs as multisite genomic modulators identified by DNA microarray
6. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cAMP-dependent protein kinase
7. Novel function of the regulatory subunit of protein kinase A: Regulation of cytochrome c oxydase activity and release of cytochrome c release
8. Combined blockade of PKA and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis
9. Protein kinase A RIα antisense inhibition of PC3M prostate cancer cell growth: bcl-2 hyperphosphorylation, Bax upregulation and Bad hypophosphorylation
10. Chemosensitization and delayed androgen independent recurrence prostate cancer with the use of antisense bcl-2 oligodeoxynucleotides
11. Oral administration of a novel taxane, an antisense targeting protein kinase A and the EGF Receptor inhibitor Iressa causes a cooperative antitumor and antiangiogenic activity